Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes
Glossary on
off
Printer Friendly Page A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes

Clinicaltrials.gov identifier:
NCT04171700


Study Contact Information:

Principal Investigator:

Kim Reiss-Binder, MD

University of Pennsylvania

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR)

About the Study

The LODESTAR study is evaluating the response of the rucaparib in people with advanced (including breast, ovarian, pancreatic, and other cancers) who have an or an acquired mutation in any of the following genes: , , , , , , , FANCA, , RAD51 or RAD51B.  NOTE: This study is no longer enrolling people.   

 

 

This Study is Open To:

 NOTE: This study is no longer enrolling people.

This Study is Not Open To:

 NOTE: This study is no longer enrolling people.